FDA green lights new Pfizer RSV vaccine amid safety concerns

The following is an excerpt from MedPage Today. In two somewhat close votes, an FDA panel of outside experts recommended the agency approve Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, despite concerns over the potential risk for Guillain Barré syndrome. By a tally of 7-4 for safety and efficacy (with one abstention in […]

Share DeepPol